HIV Infection In Vivo And In Vitro
$399,070ZIAFY2009AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications & trials
Paper 37349337Paper 35551291Paper 35264559Paper 34986348Paper 34562096Paper 33600506Paper 32966579Paper 32866318Paper 32690707Paper 31473167Paper 31139193Paper 31004012Paper 30980067Paper 30943274Paper 30787294Paper 30686586Paper 30619267Paper 30420858Paper 30388160Paper 30364428Paper 30352254Paper 30081906Paper 29997288Paper 29911997Paper 29911996Paper 29785023Paper 29781814Paper 29664020Paper 29498807Paper 29444938Paper 29364886Paper 29325070Paper 29237774Paper 29029583Paper 28580437Paper 28539448Paper 28431010Paper 28289286Paper 28133794Paper 27453467Paper 27367521Paper 26581981Paper 26223303Paper 25858157Paper 25197078Paper 24321564Paper 23847057Paper 23739328Paper 23482645Paper 22398371Paper 21116997Paper 21115690Paper 19876388Paper 19698967Paper 19656883Paper 19339347Paper 19000013Paper 18947296Paper 17913821Paper 16809286Paper 16709858Paper 15994779Paper 15967828Paper 15479838Paper 14976381Paper 14764689Paper 14722271Paper 12648460Paper 12524385Paper 12167680Paper 11986671
Abstract
HIV is known to primarily replicate in activated CD4+ T cells. In vitro studies have assessed the ability of HIV to replicate in multiple subsets of CD4+ T cells, and have identified several potential sources of T cells that are subject to infection by HIV. However, it remains unclear which CD4+ T cells are most frequently infected in vivo, and the impact of infection of these various subsets. This study seeks to define the subsets of CD4+ T cells that are naturally infected in patients, and the impact upon HIV and pathogen-specific immunity and the latent reservoir of HIV.
View original record on NIH RePORTER →